Literature DB >> 25840060

Evaluation of the expression of I-FABP and L-FABP in a necrotizing enterocolitis model after the use of Lactobacillus acidophilus.

Frances Lilian Lanhellas Gonçalves1, Lucas Manoel Mangueira Soares1, Rebeca Lopes Figueira1, Ana Leda Bertoncini Simões1, Rodrigo Melo Gallindo1, Lourenço Sbragia2.   

Abstract

BACKGROUND/
PURPOSE: Necrotizing enterocolitis (NEC) is a severe intestinal disease that primarily affects premature babies, leading to high mortality and morbidity. Probiotics represent an important alternative prophylaxis for NEC but its mechanism of action is poorly understood. Moreover, intestinal and liver-type fatty acid-binding proteins (I-FABP and L-FABP) may be utilized because markers of intestinal injury, including NEC. We aimed to evaluate the protection induced by the Lactobacillus acidophilus on the intestines of newborn rats submitted to experimental NEC using I-FABP and L-FABP as biomarkers.
METHODS: Sprague-Dawley newborn rats were divided into three groups: (1) C (control)-breast-fed; (2) NEC-subjected to NEC protocol and (3) NECP-NEC+probiotic. Morphometric, intestinal lesion, immunohistochemistry and Western blotting analysis were performed. Statistical significant differences were considered when p<0.05.
RESULTS: Intestinal weight was lower in NEC and NECP compared to C (p<0.05). Intestinal injury was lower in NECP compared to NEC. Prophylactic probiotic recovered mucosa and muscular layers' thickness to C levels (p<0.05). I-FABP and L-FABP expressions in NECP showed intermediate values between C and NEC.
CONCLUSION: L. acidophilus had a protective effect on the development of NEC and FABPs could demonstrate the degree of tissular damage of the intestine.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enterocolitis necrotizing; Fatty acid-binding proteins; Probiotics; Rats

Mesh:

Substances:

Year:  2014        PMID: 25840060     DOI: 10.1016/j.jpedsurg.2014.07.007

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

Review 1.  Prevention of Necrotizing Enterocolitis Through Manipulation of the Intestinal Microbiota of the Premature Infant.

Authors:  Kannikar Vongbhavit; Mark A Underwood
Journal:  Clin Ther       Date:  2016-02-09       Impact factor: 3.393

2.  Effects of probiotics on experimental necrotizing enterocolitis: a systematic review and meta-analysis.

Authors:  Gayatri Athalye-Jape; Shripada Rao; Sanjay Patole
Journal:  Pediatr Res       Date:  2017-10-25       Impact factor: 3.756

3.  Association of I-FABP gene polymorphism and the risk of coronary heart disease.

Authors:  Dong Yuan; Changqing Yu; Chunyu Zeng
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 4.  Impact of probiotics on necrotizing enterocolitis.

Authors:  Mark A Underwood
Journal:  Semin Perinatol       Date:  2016-11-08       Impact factor: 3.300

Review 5.  Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature.

Authors:  Bantayehu Addis Tegegne; Bekalu Kebede
Journal:  Heliyon       Date:  2022-06-22

6.  Bifidobacterium breve BBG-001 and intestinal barrier function in preterm babies: Exploratory Studies from the PiPS Trial.

Authors:  Paul Fleming; Mark Wilks; Simon Eaton; Nicola Panton; Richard Hutchinson; Abena Akyempon; Pollyanna Hardy; Michael R Millar; Kate Costeloe
Journal:  Pediatr Res       Date:  2020-09-18       Impact factor: 3.756

7.  Brain caspase-3 and intestinal FABP responses in preterm and term rats submitted to birth asphyxia.

Authors:  R L Figueira; F L Gonçalves; A L Simões; C A Bernardino; L S Lopes; O Castro E Silva; L Sbragia
Journal:  Braz J Med Biol Res       Date:  2016-06-23       Impact factor: 2.590

Review 8.  Can probiotics modulate human disease by impacting intestinal barrier function?

Authors:  Peter A Bron; Michiel Kleerebezem; Robert-Jan Brummer; Patrice D Cani; Annick Mercenier; Thomas T MacDonald; Clara L Garcia-Ródenas; Jerry M Wells
Journal:  Br J Nutr       Date:  2017-01       Impact factor: 3.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.